echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Positive data obtained by RNA cancer vaccine significantly increased the level of new antigen-specific T cells.

    Positive data obtained by RNA cancer vaccine significantly increased the level of new antigen-specific T cells.

    • Last Update: 2020-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The Granite individualized cancer vaccine and the Slate ready-to-use cancer vaccine developed by Gritstone are based on its proprietary EDGE artificial intelligence platform and tumor HLA peptide sequence.
    EDGE platform has a vast amount of human tumor data designed to predict new tumor-specific antigens (TSNa) present in patients through routine tumor biopsies.
    Granite therapy first takes biopsy tissue from the patient's body and sequences the tumor.
    then predicted TSNA by the EDGE platform and incorporated the predicted new antigen sequence into a vector containing "self-amplified RNA" (self-replicating RNA, SAM).
    these SAMs can express new antigens in the patient's body, stimulating a targeted immune response.
    previously, the U.S. FDA has granted Granite Fast Track eligibility for the treatment of microsatellite-stabilized metastatic colorectal cancer (MSS CRC).
    image source: Slate, the Gritstone Oncology website, uses the same development platform as Granite, but it contains a fixed set of shared new antigens, which are suitable for some cancer patients with the same mutation and are a ready-to-use cancer vaccine.
    currently, both vaccines are being used in Phase 1/2 clinical trials in conjunction with checkpoint inhibitors to treat patients with common solid tumors.
    in a study called GO-004, two gastroesophageal pancreatic cancer patients who had previously received anti-PD-L1 therapy and one non-small cell lung cancer patient joined the first queue of the trial, and one MSS CRC patient joined the second queue of the trial, all of whom were treated in combination with Granite and checkpoint inhibitors.
    in a study called GO-005, patients who participated in the trial were treated in combination with checkpoint inhibitors, and are still in the early stages of treatment.
    preliminary results show that the two vaccines have good tolerance and safety.
    in the GO-004 study, the lowest dose of Granite can quickly and steadily activate new antigen-specific CD8-positive T cells.
    note, these T cells can also produce IL-2 and granzyme B, indicating that they are cytotoxic. "We are pleased to see the powerful effect of activating new antigen-specific CD8-positive T cells in the first dose group of the Phase 1 study," said Dr. Andrew Allen, co-founder, president and CEO of Gritstone.

    we look forward to providing more patients with complete immunotherapy options in the coming months, providing higher doses of mature trial data.
    " : [1] Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE, Retrieved December 13, 2019, from [2] Gritstone ESMO-IO Investor Meeting Presentation,Retrieved December 13, 2019 from : | T,RNA。
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.